Business Description
vTv Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US9183852048
Share Class Description:
VTVT: Class ATotal Employee Number:
26Description
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 272.46 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-EBITDA | -0.19 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 6.38 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 34.1 | |||||
3-Year EPS without NRI Growth Rate | 31.6 | |||||
3-Year FCF Growth Rate | 28.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -20.27 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 48.42 | |||||
9-Day RSI | 51.83 | |||||
14-Day RSI | 51.64 | |||||
3-1 Month Momentum % | -12.28 | |||||
6-1 Month Momentum % | -12.53 | |||||
12-1 Month Momentum % | 113.25 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 14.36 | |||||
Quick Ratio | 14.36 | |||||
Cash Ratio | 14.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24.6 | |||||
Shareholder Yield % | -0.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -8.26 | |||||
Net Margin % | 6.11 | |||||
EBITDA Margin % | -5.23 | |||||
FCF Margin % | -28.27 | |||||
OCF Margin % | -28.27 | |||||
ROE % | 4.78 | |||||
ROA % | 3.25 | |||||
ROIC % | -503.14 | |||||
3-Year ROIIC % | 82.7 | |||||
ROC (Joel Greenblatt) % | -2603.14 | |||||
ROCE % | -3.09 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 13.7 | |||||
PB Ratio | 1.51 | |||||
Price-to-Tangible-Book | 1.51 | |||||
EV-to-EBIT | -19.48 | |||||
EV-to-Forward-EBIT | -10.19 | |||||
EV-to-EBITDA | -19.56 | |||||
EV-to-Revenue | 1.02 | |||||
EV-to-Forward-Revenue | 1.02 | |||||
EV-to-FCF | -3.62 | |||||
| Price-to-Net-Current-Asset-Value | 1.51 | |||||
| Price-to-Net-Cash | 1.52 | |||||
Earnings Yield (Greenblatt) % | -5.13 | |||||
FCF Yield % | -7.67 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VTVT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
vTv Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 36.839 | ||
| EPS (TTM) ($) | -0.93 | ||
| Beta | -0.0231 | ||
| 3-Year Sharpe Ratio | 0.32 | ||
| 3-Year Sortino Ratio | 0.71 | ||
| Volatility % | 72.73 | ||
| 14-Day RSI | 51.64 | ||
| 14-Day ATR ($) | 2.346698 | ||
| 20-Day SMA ($) | 33.48525 | ||
| 12-1 Month Momentum % | 113.25 | ||
| 52-Week Range ($) | 14 - 44 | ||
| Shares Outstanding (Mil) | 3.94 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
vTv Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
vTv Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 131 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 45 days | ||
| General meeting for 2025 | 2026-06-26 11:00 | 36.82 (+2.01%) | ||
| Alliance Global Partners Healthcare Company Showcase | 2026-05-20 16:20 | 36.49 (+4.38%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 12:30 | 35.49 (+3.27%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 32.11 (+7.36%) | ||
| 38th Annual ROTH Conference: | 2026-03-23 10:00 | 36.00 (+2.71%) | ||
| Annual report for 2025 | 2026-03-10 | 36.52 (+4.34%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-10 | 36.52 (+4.34%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 09:50 | 35.60 (-6.93%) |
Show
Entries
vTv Therapeutics Inc Frequently Asked Questions
What is vTv Therapeutics Inc(VTVT)'s stock price today?
The current price of VTVT is $34.49. The 52 week high of VTVT is $44.00 and 52 week low is $14.00.
When is next earnings date of vTv Therapeutics Inc(VTVT)?
The next earnings date of vTv Therapeutics Inc(VTVT) is 2026-08-12 Est..
Does vTv Therapeutics Inc(VTVT) pay dividends? If so, how much?
vTv Therapeutics Inc(VTVT) does not pay dividend.
Guru Commentaries on NAS:VTVT
No articles.
Press Release
Articles on vTv Therapeutics Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers